Hépato-Gastro & Oncologie Digestive


Management of anemia in patients treated with chemotherapy for digestive cancer Volume 26, supplement 1, Octobre 2019

  • [1] Ludwig H., Van Belle S., Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293-2306. 15
  • [2] Ludwig H, Aapro M, Bokemeyer C, et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer 2014 ; 22 (8) : 2197-206.
  • [3] Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer : ESMO Clinical Practice Guidelines. Ann Oncol 2018 ; 29 (Suppl. 4) : iv96-110.
  • [4] Douillard J.Y., Cunningham D., Roth A.D. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet. 2000;355:1041-1047. 9209
  • [5] Falcone A., Ricci S., Brunetti I. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-1676. 13
  • [6] Assenat E., Desseigne F., Thezenas S. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: A phase II trial. Oncologist. 2011;16:1557-1564. 11
  • [7] Ychou M., Viret F., Kramar A. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) : a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008;62:195-201. 2
  • [8] Conroy T., Desseigne F., Ychou M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825. 19
  • [9] Von Hoff D.D., Ervin T., Arena F.P. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-1703. 18
  • [10] Wilke H., Muro K., Van Cutsem E. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224-1235. 11
  • [11] Hironaka S., Ueda S., Yasui H. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum : WJOG 4007 trial. J Clin Oncol. 2013;31:4438-4444. 35
  • [12] Van Cutsem E., Boni C., Tabernero J. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: A randomized phase II study. Ann Oncol. 2015;26:149-156. 1
  • [13] Van Cutsem E., Moiseyenko V.M., Tjulandin S. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol. 2006;24:4991-4997. 31
  • [14] Shah M.A., Janjigian Y.Y., Stoller R. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol. 2015;33:3874-3879. 33
  • [15] Mayer R.J., Van Cutsem E., Falcone A. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909-1919. 20
  • [16] Grothey A., Van Cutsem E., Sobrero A. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303-312. 9863
  • [17] Ludwig H., Strasser K. Symptomatology of anemia. Semin Oncol. 2001;28:7-14. 2 Suppl. 8
  • [18] Yellen S.B., Cella D.F., Webster K., Blendowski C., Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63-74. 2
  • [19] Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34:13-19. 3 Suppl. 2
  • [20] Glaser C.M., Millesi W., Kornek G.V. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys. 2001;50:705-715. 3
  • [21] Hedenus M., Vansteenkiste J., Kotasek D., Austin M., Amado R.G. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: Disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol. 2005;23:6941-6948. 28
  • [22] Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer : a systemic, quantitative review. Cancer 2001 ; 91 (12) : 2214-21.
  • [23] Morganti A.G., Forni F., Macchia G. Chemoradiation of unresectable pancreatic carcinoma: Impact of pretreatment hemoglobin level on patterns of failure. Strahlenther Onkol. 2003;179:87-92. 2
  • [24] Littlewood T.J. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol. 2001;28:49-53. 2 Suppl. 8
  • [25] Gabrilove J.L., Cleeland C.S., Livingston R.B., Sarokhan B., Winer E., Einhorn L.H. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients : improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875-2882. 11
  • [26] Cella D., Kallich J., McDermott A., Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Ann Oncol. 2004;15:979-986. 6
  • [27] Crawford J., Cella D., Cleeland C.S. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888-895. 4
  • [28] Hudis C.A., Van Belle S., Chang J., Muenstedt K. rHuEPO and treatment outcomes: The clinical experience. Oncologist. 2004;9:55-69. Suppl. 5
  • [29] Assurance Maladie. Bon usage du médicament - Agents stimulants l’érythropoïèse en cancérologie - Janvier 2016. https://www.ameli.fr/sites/default/files/Documents/5043/document/ase-cancerologie_assurance-maladie.pdf.
  • [30] Glaspy J., Crawford J., Vansteenkiste J. Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102:301-315. 2